China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli Lilly & Co. (NYSE: LLY) to explore 3D printing technology for precise, programmed drug release in the gastrointestinal (GI) tract.
Partnership Goals
The collaboration will focus on two key areas:
- Excipient and Process Optimization: Studying excipient properties and 3D printing parameters to ensure drug stability during formulation, printing, and release.
- Targeted Dosage Design: Developing a unique 3D structure to enable programmed drug release in specific intestinal regions, aiming to improve oral drug bioavailability.
Triastek’s Technology Platform
Triastek utilizes its MED platform for 3D drug design and printing of solid dosage forms. The firm also offers CRO/CMO services and conducts in-house drug development, targeting improved formulations eligible for the FDA’s 505(b)(2) pathway. Triastek has received two FDA IND approvals to date.-Fineline Info & Tech
